Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

RECOVERY
  NCT04381936		 RCTlopinavir/ritonavirstandard of careCOVID 19 hospitalizedsome concern
1616/3424 inconclusive
  • inconclusive 3 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
the trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed randomisation to that treatment arm
SOLIDARITY (lopi/rito)
  NCT04315948		 RCTlopinavir/ritonavirstandard of careCOVID 19 hospitalizedsome concern
1399/1372 inconclusive
  • inconclusive 0 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias

COVID-19 mild to moderate meta-analysis

ELACOI (lopinavir/ritonavir)
  NCT04252885		 RCTlopinavir/ritonavirstandard of careCOVID-19 mild to moderatesome concern
21/7 inconclusive

    COVID-19 severe or critically meta-analysis

    Cao
          ChiCTR2000029308    		 RCTlopinavir/ritonavirstandard of careCOVID-19 severe or criticallysome concern
    		99/100 suggested
    • inconclusive 31 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 94 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
    REMAP-CAP (lopinavir/ritonavir only)
          NCT02735707    		 RCTlopinavir/ritonavirstandard of careCOVID-19 severe or criticallysome concern
    		268/377 safety concern
    • statistically significant 17 % decrease in hospital discharge with a moderate degree of certainty due to some concern in risk of bias
    1 study excluded by filtering options (0 RCT / 1 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

     

    - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons